Drug Profile
Long-acting peginterferon alpha- Bolder BioTechnology
Alternative Names: BBT-012Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Bolder BioTechnology
- Class Antivirals; Interferons
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Viral infections
- No development reported Cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
- 29 Oct 2021 BBT 012 is still in preclinical trials for Cancer in USA (Parenteral) (Bolder Biotechnology pipeline, October 2021)
- 20 May 2020 Long-acting peginterferon alpha- Bolder BioTechnology is available for licensing as of 20 May 2020. http://www.bolderbio.com/